NCT01164163: INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease |
|
|
| Completed | 1 | 49 | US | ruxolitinib phosphate, laboratory biomarker analysis, pharmacological study | Children's Oncology Group, National Cancer Institute (NCI) | Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Childhood Solid Tumor, Protocol Specific | 10/14 | | | |